Host |
Rabbit |
Klon |
polyclonal |
Format |
Lyophilised |
Methode |
EL, WB |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant mouse IL-4 |
Interleukin 4 (IL-4)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Lyophilised |
RUO |
609-0951 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Lyophilised |
Methode |
IHC(P), EL, WB |
Vorbehandlung |
HIER in Citrate Buffer |
Verdünnung |
0.25 - 0.5 µg/ml |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant human IL-6 |
Interleukin 6 (IL-6)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Lyophilised |
RUO |
609-0985 |
-
|
Host |
Rat |
Klon |
JES3-12G8 |
Format |
Purified |
Methode |
EL, WB, FL, P |
Isotyp |
Rat IgG2a |
Verdünnung |
Human IL-10 expressed by COS cells |
Interleukin 10 (IL-10, CSIF)
|
Zytomed Systems GmbH |
JES3-12G8 |
500 µg |
Purified |
RUO |
609-0862 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Lyophilised |
Methode |
EL, WB |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant human IL-17 |
Interleukin 17 (IL-17)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Lyophilised |
RUO |
609-0903 |
-
|
Host |
Rabbit |
Klon |
SP105 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near the internal region of human J-chain |
Lokalisation |
Cytoplasm |
J-Chain
|
Zytomed Systems GmbH |
SP105 |
1 ml |
Concentrate |
RUO |
510-4054 |
-
|
Host |
Mouse |
Klon |
Mc19-9 |
Format |
Purified |
Methode |
F, EL, WB, IP |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human J Chain |
J Chain
|
Zytomed Systems GmbH |
Mc19-9 |
200 µg |
Purified |
RUO |
610-0001 |
-
|
Host |
Mouse+Rabbit |
Klon |
L1C1+polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, bone marrow |
Verdünnung |
- |
Isotyp |
Mouse IgG1+not determined |
Lokalisation |
Cytoplasm |
Kappa + Lambda
|
Biocare Medical |
L1C1+polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API3159DSAA |
-
|
Host |
Rabbit |
Klon |
SP148 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Free kappa light chain from pooled human IgG kappa myeloma sera. |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zytomed Systems GmbH |
SP148 |
0.5 ml |
Concentrate |
RUO |
511-4482 |
-
|
Host |
Rabbit |
Klon |
SP148 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Free kappa light chain from pooled human IgG kappa myeloma sera. |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zytomed Systems GmbH |
SP148 |
1 ml |
Concentrate |
RUO |
511-4484 |
-
|
Host |
Mouse |
Klon |
L1C1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified citrate buffer pH 6.0 |
Positivkontrolle |
Tonsil or bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Biocare Medical |
L1C1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3149A |
-
|
Host |
Mouse |
Klon |
L1C1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified citrate buffer pH 6.0 |
Positivkontrolle |
Tonsil or bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Biocare Medical |
L1C1 |
1 ml |
Concentrate |
CE/IVD |
ACI3149C |
-
|
Host |
Mouse |
Klon |
L1C1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified citrate buffer pH 6.0 |
Positivkontrolle |
Tonsil or bone marrow |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Biocare Medical |
L1C1 |
6 ml |
Ready-to-use |
CE/IVD |
API3149AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR015 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:500 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP025 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:500 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP025-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:500 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP025-05 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM81 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human IGKC protein |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zeta Corporation |
ZM81 |
1 ml |
Concentrate |
CE/IVD |
Z2532ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM81 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human IGKC protein |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zeta Corporation |
ZM81 |
7 ml |
Ready-to-use |
CE/IVD |
Z2532MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM81 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human IGKC protein |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zeta Corporation |
ZM81 |
0.5 ml |
Concentrate |
CE/IVD |
Z2532MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM81 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human IGKC protein |
Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zeta Corporation |
ZM81 |
0.1 ml |
Concentrate |
CE/IVD |
Z2532MT |
-
|
Host |
Mouse |
Klon |
KP-53 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG2b |
Lokalisation |
Cytoplasm |
Kappa light chain (KP-53)
|
Diagnostic Biosystems |
KP-53 |
1 ml |
Concentrate |
CE/IVD |
MOB544 |
-
|
Host |
Mouse |
Klon |
KP-53 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG2b |
Lokalisation |
Cytoplasm |
Kappa light chain (KP-53)
|
Diagnostic Biosystems |
KP-53 |
0.1 ml |
Concentrate |
CE/IVD |
MOB544-01 |
-
|
Host |
Mouse |
Klon |
KP-53 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG2b |
Lokalisation |
Cytoplasm |
Kappa light chain (KP-53)
|
Diagnostic Biosystems |
KP-53 |
0.5 ml |
Concentrate |
CE/IVD |
MOB544-05 |
-
|
Host |
Mouse |
Klon |
KP-53 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
IgG2b |
Lokalisation |
Cytoplasm |
Kappa light chain (KP-53)
|
Diagnostic Biosystems |
KP-53 |
6 ml |
Ready-to-use |
CE/IVD |
PDM055 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Verdünnung |
1:20 - 1:40 |
Isotyp |
Rabbit Ig |
Kappa Light Chain FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F001 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Verdünnung |
1:20 - 1:40 |
Isotyp |
Rabbit Ig |
Kappa Light Chain FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F001-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Lyophilised |
Methode |
EL, WB, IHC(P) |
Vorbehandlung |
Proteinase K |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant human KGF |
Keratinocyte Growth Factor, Recombinant Human (KGF, Fibroblast Growth Factor 7, FGF-7)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Lyophilised |
RUO |
611-0045 |
-
|
Host |
Mouse |
Klon |
MIB-1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Human recombinant peptide corresponding to a 1002 bp Ki-67 cDNA fragment |
Lokalisation |
Nucleus |
Ki-67
|
Biocare Medical |
MIB-1 |
6 ml |
Ready-to-use |
CE/IVD |
API3156AA |
-
|
Host |
Mouse |
Klon |
MIB-1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Human recombinant peptide corresponding to a 1002 bp Ki-67 cDNA fragment |
Lokalisation |
Nucleus |
Ki-67
|
Biocare Medical |
MIB-1 |
25 ml |
Ready-to-use |
CE/IVD |
API3156H |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Ki-67
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR048 |
-
|
Host |
Rabbit |
Klon |
SP6 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Ki-67
|
Diagnostic Biosystems |
SP6 |
1 ml |
Concentrate |
CE/IVD |
RMAB004 |
-
|
Host |
Rabbit |
Klon |
SP6 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Ki-67
|
Diagnostic Biosystems |
SP6 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB004-01 |
-
|
Host |
Rabbit |
Klon |
SP6 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Ki-67
|
Diagnostic Biosystems |
SP6 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB004-05 |
-
|
Host |
Rabbit |
Klon |
SP6 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Ki-67
|
Diagnostic Biosystems |
SP6 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD004 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Ki-67
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP026 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Ki-67
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP026-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Ki-67
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP026-05 |
-
|
Host |
Mouse |
Klon |
MIB-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
Verdünnung |
1:150 - 1:300 |
Isotyp |
IgG1 /κ |
Verdünnung |
Nuclear fractions of Hodgkin lymphoma cell line L248 of human origin |
Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
MIB-1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2305ML |
-
|
Host |
Mouse |
Klon |
MIB-1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Nuclear fractions of Hodgkin lymphoma cell line L248 of human origin |
Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
MIB-1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2305MP |
-
|
Host |
Mouse |
Klon |
MIB-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
Verdünnung |
1:150 - 1:300 |
Isotyp |
IgG1 /κ |
Verdünnung |
Nuclear fractions of Hodgkin lymphoma cell line L248 of human origin |
Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
MIB-1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2305MS |
-
|
Host |
Mouse |
Klon |
MIB-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
Verdünnung |
1:150 - 1:300 |
Isotyp |
IgG1 /κ |
Verdünnung |
Nuclear fractions of Hodgkin lymphoma cell line L248 of human origin |
Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
MIB-1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2305MT |
-
|
Host |
Mouse |
Klon |
ZM67 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG/κ |
Verdünnung |
Recombinant human Ki67 protein fragment (around aa2293-2478) |
Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
ZM67 |
1.0 ml |
Concentrate |
CE/IVD |
Z2377ML |
-
|
Host |
Mouse |
Klon |
ZM67 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
Verdünnung |
- |
Isotyp |
IgG/κ |
Verdünnung |
Recombinant human Ki67 protein fragment (around aa2293-2478) |
Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
ZM67 |
7 ml |
Ready-to-use |
CE/IVD |
Z2377MP |
-
|
Host |
Mouse |
Klon |
ZM67 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG/κ |
Verdünnung |
Recombinant human Ki67 protein fragment (around aa2293-2478) |
Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
ZM67 |
0.5 ml |
Concentrate |
CE/IVD |
Z2377MS |
-
|
Host |
Mouse |
Klon |
ZM67 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG/κ |
Verdünnung |
Recombinant human Ki67 protein fragment (around aa2293-2478) |
Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
ZM67 |
0.1 ml |
Concentrate |
CE/IVD |
Z2377MT |
-
|
Host |
Mouse+Rabbit |
Klon |
DVB-2+polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1+not determined |
Lokalisation |
Nuclear and cytoplasmic |
Ki-67 + Caspase-3
|
Biocare Medical |
DVB-2+polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PPM240DSAA |
-
|
Host |
Mouse + Rabbit |
Klon |
MIB-1+BC1+EP17+EP30 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast carcinoma |
Verdünnung |
- |
Isotyp |
IgG/kappa + IgG |
Lokalisation |
Nucleus and cytoplasm |
Ki-67 + CK7/8/18
|
Biocare Medical |
MIB-1+BC1+EP17+EP30 |
6 ml |
Ready-to-use |
CE/IVD |
API3192DSAA |
-
|
Host |
Mouse |
Klon |
H-6 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Lokalisation |
Nucleus |
Ku (p70)
|
Diagnostic Biosystems |
H-6 |
1 ml |
Concentrate |
CE/IVD |
MOB557 |
-
|
Host |
Mouse |
Klon |
H-6 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Lokalisation |
Nucleus |
Ku (p70)
|
Diagnostic Biosystems |
H-6 |
0.1 ml |
Concentrate |
CE/IVD |
MOB557-01 |
-
|
Host |
Mouse |
Klon |
H-6 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Lokalisation |
Nucleus |
Ku (p70)
|
Diagnostic Biosystems |
H-6 |
0.5 ml |
Concentrate |
CE/IVD |
MOB557-05 |
-
|